Analyst Consensus ?
ConsensusBuy29 ratings
Bullish1862.1%
Neutral1034.5%
Bearish13.4%
Willis Towers Watson Public Limited Company · WTW · FY2026 Q3 · Calendar Q4 2026
WTW posts Q3 growth while lowering full-year organic outlook
WTW's Q3 results support a constructive long-term operating thesis through organic growth, margin expansion, AI-enabled products and cost savings. The near-term evidence is mixed because full-year organic growth guidance was lowered and execution risks remain in BD&O and the Middle East.
Reported Before market openNASDAQFinancial Services
$29.87B market cap
70quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $3.59
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.45B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-0.3%
Event window
SPY move
-0.4%
Same window
Abnormal move
+0.1%
Stock minus SPY
Volume
2.0×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
WTWSPY benchmark
Ask FN2 about WTW FY2026 Q3
Transcript, numbers and history already loaded
What drove WTW's -0.3% move after FY2026 Q3 earnings?What changed in WTW's guidance and outlook in FY2026 Q3?Give me the bull and bear case for WTW after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The company reported Q3 organic growth, adjusted EPS growth and margin expansion, while lowering full-year organic growth guidance to low-to-mid single-digit growth. Management also highlighted new AI products, broader Propel deployment and the pending BMS Re U.S. acquisition.
Guidance delta
Full-year organic growth guidance was lowered to low-to-mid single-digit growth; BD&O is expected to be flat.
Key takeaways
- Q3 organic revenue grew 4%, with adjusted EPS growth of 18% and 150 basis points of margin expansion.
- Propel is supporting new AI-enabled products and operating efficiencies across the firm.
- Specialty-lines demand and large contracts supported growth, while BD&O delays and Middle East headwinds weighed on the outlook.
- Willis Re is expanding through the pending BMS Re U.S. reinsurance acquisition; buybacks are on track to exceed $1 billion for the year.
Management priorities
- Roll out the Neuron AI operating model to 10 additional countries in Q4.
- Launch an AI-enabled global actuarial coordination solution in early 2027.
- Continue Propel cost savings, targeting $400 million of run-rate savings by 2028.
- Integrate BMS Re's U.S. reinsurance business into Willis Re.
Follow WTW with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$320.73Current
$247Low
$341.75Average
$405High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 12, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Oct 7, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Oct 7, 2026 |
| UBS | Buy | Buy | Maintain | Oct 6, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 6, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 20, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Aug 4, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Aug 3, 2026 |
| Citigroup | Neutral | Buy | Downgrade | Aug 3, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Aug 3, 2026 |
| Truist Securities | Buy | Buy | Maintain | Jul 31, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 15, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 1, 2026 |
| BMO Capital | Outperform | Market Perform | Upgrade | May 1, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Apr 14, 2026 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Sep 22, 2025 |
| Jefferies | Buy | Buy | Maintain | Apr 11, 2025 |
| Roth MKM | Buy | Buy | Maintain | Jul 26, 2024 |
| Stifel | Hold | Hold | Maintain | Feb 7, 2024 |
| Baird | Outperform | Outperform | Maintain | May 1, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Dec 15, 2022 |
| MKM Partners | Buy | Buy | Maintain | Dec 5, 2022 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Oct 19, 2021 |
| Deutsche Bank | Hold | Hold | Maintain | May 3, 2021 |
| CFRA | Buy | Hold | Upgrade | Mar 8, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jul 10, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Jan 15, 2018 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Jun 23, 2016 |
| JP Morgan | Underweight | Underweight | Maintain | Feb 9, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $320.73. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Analyst unavailable | $364 | $296.26 | +13.5% | Oct 12, 2026 |
| Mizuho Securities | Analyst unavailable | $349 | $291.98 | +8.8% | Oct 7, 2026 |
| Barclays | Analyst unavailable | $332 | $291.98 | +3.5% | Oct 7, 2026 |
| Morgan Stanley | Bob Huang | $310 | $290.98 | -3.3% | Oct 6, 2026 |
| Mizuho Securities | Yaron Kinar | $380 | $321.97 | +18.5% | Sep 16, 2026 |
| Morgan Stanley | Analyst unavailable | $350 | $327.9 | +9.1% | Aug 19, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $380 | $341.09 | +18.5% | Aug 3, 2026 |
| UBS | Brian Meredith | $405 | $341.04 | +26.3% | Aug 3, 2026 |
| Morgan Stanley | Bob Huang | $315 | $341.39 | -1.8% | Aug 3, 2026 |
| Robert W. Baird | Mark Marcon | $385 | $336.05 | +20.0% | Jul 31, 2026 |
| Mizuho Securities | Yaron Kinar | $406 | $336.05 | +26.6% | Jul 31, 2026 |
| Atlantic Equities | Analyst unavailable | $360 | $287.3 | +12.2% | Jul 15, 2026 |
| Piper Sandler | Paul Newsome | $317 | $288.74 | -1.2% | Jul 15, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $344 | $292.58 | +7.3% | Jul 9, 2026 |
| Mizuho Securities | Analyst unavailable | $361 | $292.58 | +12.6% | Jul 9, 2026 |
| UBS | Analyst unavailable | $382 | $291.47 | +19.1% | Jul 8, 2026 |
| UBS | Analyst unavailable | $374 | $258.12 | +16.6% | Jun 9, 2026 |
| Raymond James | Analyst unavailable | $340 | $261.92 | +6.0% | May 6, 2026 |
| Mizuho Securities | Analyst unavailable | $338 | $259.37 | +5.4% | May 5, 2026 |
| Morgan Stanley | Analyst unavailable | $275 | $259 | -14.3% | May 1, 2026 |
| Robert W. Baird | Mark Marcon | $335 | $260.24 | +4.4% | May 1, 2026 |
| Evercore ISI | Analyst unavailable | $360 | $263.78 | +12.2% | May 1, 2026 |
| Piper Sandler | Paul Newsome | $283 | $256.2 | -11.8% | May 1, 2026 |
| BMO Capital | Analyst unavailable | $300 | $256.2 | -6.5% | May 1, 2026 |
| Truist Financial | Mark Hughes | $320 | $256.33 | -0.2% | Apr 30, 2026 |
| Mizuho Securities | Analyst unavailable | $353 | $285.58 | +10.1% | Apr 13, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $354 | $287.86 | +10.4% | Apr 9, 2026 |
| Piper Sandler | Paul Newsome | $341 | $301.81 | +6.3% | Feb 23, 2026 |
| UBS | Analyst unavailable | $409 | $319.38 | +27.5% | Feb 9, 2026 |
| Truist Financial | Analyst unavailable | $400 | $338.86 | +24.7% | Feb 4, 2026 |
| Mizuho Securities | Analyst unavailable | $392 | $335.1 | +22.2% | Feb 4, 2026 |
| Wells Fargo | Analyst unavailable | $379 | $335.1 | +18.2% | Feb 4, 2026 |
| Cantor Fitzgerald | Ryan Tunis | $345 | $329.28 | +7.6% | Jan 14, 2026 |
| Mizuho Securities | Analyst unavailable | $388 | $327.42 | +21.0% | Jan 14, 2026 |
| Wells Fargo | Elyse Greenspan | $366 | $329.45 | +14.1% | Jan 13, 2026 |
| Barclays | Analyst unavailable | $318 | $331.38 | -0.9% | Jan 8, 2026 |
| Goldman Sachs | Analyst unavailable | $375 | $331.38 | +16.9% | Jan 7, 2026 |
| Evercore ISI | Analyst unavailable | $383 | $333.38 | +19.4% | Jan 7, 2026 |
| Mizuho Securities | Yaron Kinar | $386 | $330.76 | +20.4% | Dec 15, 2025 |
| Wells Fargo | Analyst unavailable | $356 | $325.52 | +11.0% | Dec 12, 2025 |
| Barclays | Alex Scott | $303 | $317.26 | -5.5% | Nov 20, 2025 |
| UBS | Brian Meredith | $398 | $348.68 | +24.1% | Oct 8, 2025 |
| Barclays | Alex Scott | $341 | $349.93 | +6.3% | Oct 8, 2025 |
| Piper Sandler | Analyst unavailable | $387 | $347.07 | +20.7% | Oct 6, 2025 |
| Evercore ISI | Analyst unavailable | $387 | $343.95 | +20.7% | Oct 1, 2025 |
| Wells Fargo | Analyst unavailable | $377 | $342.2 | +17.5% | Sep 30, 2025 |
| Morgan Stanley | Bob Huang | $345 | $329.31 | +7.6% | Aug 18, 2025 |
| Jefferies | Yaron Kinar | $382 | $311 | +19.1% | Dec 20, 2024 |
| Raymond James | Greg Peters | $400 | $331.79 | +24.7% | Dec 5, 2024 |
| Barclays | Alex Scott | $278 | $294.38 | -13.3% | Sep 4, 2024 |
| Wells Fargo | Elyse Greenspan | $321 | $281.52 | +0.1% | Jul 26, 2024 |
| Truist Financial | Mark Hughes | $335 | $280.81 | +4.4% | Jul 26, 2024 |
| CFRA | Catherine Seifert | $315 | $280.96 | -1.8% | Jul 26, 2024 |
| Evercore ISI | David Motemaden | $319 | $277.6 | -0.5% | Jul 25, 2024 |
| BMO Capital | Michael Zaremski | $298 | $272.2 | -7.1% | Feb 12, 2024 |
| Wells Fargo | Jared Shaw | $288 | $247.07 | -10.2% | Jan 11, 2024 |
| BMO Capital | Michael Zaremski | $205 | $203.44 | -36.1% | Aug 8, 2023 |
| Goldman Sachs | Robert Cox | $290 | $237.74 | -9.6% | Feb 27, 2023 |
| Goldman Sachs | Analyst unavailable | $271 | $256.13 | -15.5% | Jan 9, 2023 |
| Raymond James | Analyst unavailable | $280 | $245.24 | -12.7% | Dec 29, 2022 |
| Credit Suisse | Analyst unavailable | $302 | $243.42 | -5.8% | Dec 15, 2022 |
| Citigroup | Analyst unavailable | $247 | $245.63 | -23.0% | Dec 15, 2022 |
| MKM Partners | Analyst unavailable | $285 | $248 | -11.1% | Dec 5, 2022 |
| Morgan Stanley | Analyst unavailable | $240 | $236.06 | -25.2% | Nov 22, 2022 |
| Goldman Sachs | Robert Cox | $227 | $194.85 | -29.2% | Jul 15, 2022 |
Track every rating change on WTW the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationWillis Towers Watson Public Limited Company (WTW) functions as a global provider of comprehensive consulting, brokerage, and solutions services. Its operations are structured across two primary divisions: Health, Wealth and Career, and Risk and Broking. Within the Health, Wealth and Career segment, WTW furnishes actuarial guidance, plan development, and administrative assistance for conventional pension and retirement savings schemes. It also delivers consulting, brokerage, and management services for health and group employee benefit programs, along with outsourced benefits administration. Furthermore, the company offers strategic counsel, analytical data, specialized software, and various products designed to help clients effectively manage their overall compensation and human capital challenges. The Risk and Broking division extends expertise in risk management, insurance placement, and advisory services, covering sectors such as property and casualty, aerospace, construction, and marine.…
Historical context
All WTW earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| TW Tradeweb Markets Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -0.3% | Tradeweb posts 14.9% growth as electronic trading expands |
| ICE Intercontinental Exchange, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +5.5% | ICE posts record Q3 as data, energy and rates growth accelerates |
| BBVA Banco Bilbao Vizcaya Argentaria, S.A. | FY2026 Q3 · Calendar Q4 2026 | — | -2.5% | BBVA sustains strong growth and profitability in Q3 |
| TROW T. Rowe Price Group, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +1.3% | T. Rowe Price pairs Q4 flow hopes with ETF and SMA momentum |
| ING ING Groep N.V. | FY2026 Q3 · Calendar Q4 2026 | — | -2.1% | ING pairs strong Q3 execution with costly wholesale restructuring |
| SAN Banco Santander, S.A. | FY2026 Q3 · Calendar Q4 2026 | 0.0% | -6.3% | Santander reaffirms guidance as transformation and integrations progress |
Latest beats and misses
Who reports nextBeat on EPS
- ARFY2026 Q3 · October 28, 2026+22.3% EPS-2.2% move
- INVHFY2026 Q3 · October 28, 2026+49.5% EPS-0.4% move
- AEMFY2026 Q3 · October 28, 2026+5.7% EPS-3.9% move
- ORLYFY2026 Q3 · October 28, 2026+4.3% EPS-2.7% move
- STRLFY2026 Q3 · October 28, 2026+22.3% EPS-0.4% move
- KGCFY2026 Q3 · October 28, 2026+8.7% EPS-6.1% move
Get the WTW recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-29T19:11:36.054872+00:00
- FN2 earnings calendar · 2026-10-29T01:23:20.584741+00:00
- Polygon adjusted daily market bars · 2026-10-29T21:40:43.338478+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-29T21:40:43.335807+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-29. For educational purposes only; not investment advice.